An assessment of the joint associations of aspirin and statin use with C-reactive protein concentration

American Heart Journal

Volumn 156, Issue 1, 2008, Pages 106-111

  Fisher, Matt ^a   Cushman, Mary ^b   Knappertz, Volker ^a   Howard, George ^c  

^a BAYER CORPORATION   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; STATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG USE; FEMALE; HISTORY; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; ASPIRIN; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PROBABILITY; PROGNOSIS; REFERENCE VALUES; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 45849087989     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.12.035     Document Type: Article

References (31)

1. Tsimikas S., Willerson J.T., and Ridker P.M. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 47 8 Suppl (2006) C19-C31
2. Yeh E.T.H. CRP as a mediator of disease. Circulation 109 (2004) 11-14
3. Cao J.J., Thach C., Manolio T.A., et al. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation 108 (2003) 166-170
4. Koenig W., Sund M., Fröhlich M., et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants of Cardiovascular Disease) Augsberg Cohort Study, 1984 to1992. Circulation 99 (1999) 237-242
5. Ridker P.M., Hennekens C.H., Buring J.E., et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
6. Ridker P.M., Rifai N., Rose L., et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
7. Ridker P.M., Cushman M., Stampfer M.J., et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97 (1998) 425-428
8. Eidelman R.S., Herbert P.R., Weisman S.M., et al. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 163 (2003) 2006-2010
9. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 524 (2002) 71-86
10. Ikonomidis I., Andreotti F., Economou E., et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 100 (1999) 793-798
11. Solheim S., Arnesen H., Eikvar L., et al. Influence of aspirin on inflammatory markers in patients after acute myocardial infarction. Am J Cardiol 92 (2003) 843-845
12. Azar R.R., Klayme S., Germanos M., et al. Effects of aspirin (325 mg/day) on serum high-sensitivity C-reactive protein, cytokines, and adhesion molecules in healthy volunteers. Am J Cardiol 92 (2003) 236-239
13. Feldman M., Jialal I., Devaraj S., et al. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol 37 (2001) 2036-2041
14. Feng D., Tracy R.P., Lipinska I., et al. Effect of short-term aspirin use on C-reactive protein. J Thromb Thrombolysis 9 (2000) 37-41
15. Ridker P.M., Cushman M., Stampfer M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997) 973-979 Erratum in: N Engl J Med. 1997;337:356
16. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
17. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239 Erratum in: Circulation. 2004;110:763
18. Plenge J.K., Hernandez T.L., Weil K.M., et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 106 (2002) 1447-1452
19. Kent S.M., Flaherty P.J., Coyle L.C., et al. Effect of atorvastatin and pravastatin on serum C-reactive protein. Am Heart J 145 (2003) e8
20. Ballantyne C.M., Houri J., Notarbartolo A., et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia. Circulation 107 (2003) 2409-2415
21. Hennekens C.H., Sacks F.M., Tonkin A., et al. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease. Arch Intern Med 164 (2004) 40-44
22. Howard V.J., Cushman M., Pulley L.V., et al. The REasons for Geographic and Racial Differences in Stroke (REGARDS) Study: objectives and design. Neuroepidemiology 25 (2005) 135-143
23. Neter J., Kutner M.H., and Wasserman W. Applied linear statistical models. 4th ed. (2004), New York, NY: McGraw-Hill
24. Mehta J.L., Chen J., Yu F., et al. Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells. Cardiovasc Res 64 (2004) 243-249
25. Chen J., Liu H., Liu Y., et al. Combination of aspirin and pravastatin dramatically reduces oxidative stress and the expression of LOX-1 and adhesion molecules: novel insight into the mechanism of action of aspirin and statins [abstract]. J Am Coll Cardiol 47 (2006) 340A
26. Hofnagel O., Luechtenborg B., Eschert H., et al. Pravastatin inhibits expression of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in Watanabe heritable hyperlipidemic rabbits: a new pleiotropic effect of statins. Arterioscler Thromb Vasc Biol 26 (2006) 604-610
27. Li D., Liu L., Chen H., et al. LOX-1, an oxidized LDL endothelial receptor, induces CD40/CD40L signaling in human coronary artery endothelial cells. Arterioscler Thromb Vasc Biol 23 (2003) 816-821
28. Lin R., Liu J., Peng N., et al. Lovastatin reduces nuclear factor kappaB activation induced by C-reactive protein in human vascular endothelial cells. Biol Pharm Bull 28 (2005) 1630-1634
29. Awtry E., and Loscalzo J. Aspirin. Circulation 101 (2000) 1206-1218
30. Taubert D., Berkels R., Grosser N., et al. Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action. Br J Pharmacol 143 (2004) 159-165
31. Chiang N., Burmudez E.A., Ridker P.M., et al. Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci USA 101 (2004) 15178-15183